33.76

1.96% 0.65

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Discussions Forecast

Castle Biosciences Inc stock is traded at $33.76, with a volume of 108.27K. It is up +1.96% in the last 24 hours and down -4.90% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$33.11

Open:

$33.13

24h Volume:

108.27K

Relative Volume:

0.32

Market Cap:

$1.03B

Revenue:

$339.92M

Net Income/Loss:

$-12.83M

P/E Ratio:

-78.60

EPS:

-0.4295

Net Cash Flow:

$4.52M

1W Performance:

+0.15%

1M Performance:

-4.90%

6M Performance:

+37.12%

1Y Performance:

+49.98%

1-Day Range:

$32.48

$33.95

1-Week Range:

$32.23

$34.52

52-Week Range:

$17.72

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1051)

Industry

Diagnostics & Research (44)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

883

Twitter

@castlebio

Next Earnings Date

2026-11-02

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, NTRA, A, IQV

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	33.76	1.03B	339.92M	-12.83M	4.52M	-0.4295
TMO Thermo Fisher Scientific Inc	693.47	256.41B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	231.63	162.83B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	402.14	57.97B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	176.41	49.74B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	269.58	44.37B	16.63B	1.39B	2.12B	8.0674

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-26	Initiated	Roth Capital	Buy
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Oct 11, 2026

Form 4 Castle Biosciences Inc For: 10 October By Investing.com - Investing.com South Africa

Oct 11, 2026

Oct 10, 2026

Castle Biosciences president and CEO Derek Maetzold sells $515k stock - Investing.com

Oct 10, 2026

Form 4 Castle Biosciences Inc For: 10 October By Investing.com - Investing.com Nigeria

Oct 10, 2026

Oct 07, 2026

Castle Biosciences CEO Derek Maetzold Executes Option Exercise and Sells 14,496 Shares on October 5, 2026 - Kalkine Media

Oct 07, 2026

Oct 05, 2026

Castle Biosciences Officer Derek Maetzold Files Form 144 for 28,992 Share Sale Valued Over $1 Million - Kalkine Media

Oct 05, 2026

An officer and two trusts propose selling 28,992 shares of Castle Biosciences (CSTL). - Stock Titan

Oct 05, 2026

Castle Biosciences COO Kristen M. Oelschlager Exercises Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media

Oct 05, 2026

Oct 02, 2026

Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,577 Shares - GuruFocus

Oct 02, 2026

Oct 01, 2026

Castle Biosciences CCO Executes 6,577-Share Sale Under Rule 10b5-1 Plan - Kalkine Media

Oct 01, 2026

Officer Kristen Oelschlager proposes selling 4,153 Castle Biosciences (CSTL) shares. - stocktitan.net

Oct 01, 2026

Sep 27, 2026

Castle Biosciences CEO sells $512k in stock - Investing.com

Sep 27, 2026

Sep 26, 2026

Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Castle Biosciences CEO sells $512k in stock By Investing.com - Investing.com Nigeria

Sep 26, 2026

Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com India

Sep 26, 2026

Castle Biosciences (NASDAQ:CSTL) Upgraded to "Buy" at Wall Street Zen - marketbeat.com

Sep 26, 2026

Sep 21, 2026

How Investors May Respond To Castle Biosciences Stock After New Test Validation Studies - simplywall.st

Sep 21, 2026

Sep 17, 2026

Castle Biosciences (NASDAQ: CSTL) Chief Commercial Officer Juvenal Tobin W Sells 6,600 Shares Between $32.32 and $35.14 - Kalkine Media

Sep 17, 2026

Sep 16, 2026

Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,600 Shares - GuruFocus

Sep 16, 2026

6,600 Castle Biosciences (CSTL) shares sold under preset 10b5-1 plan - Stock Titan

Sep 16, 2026

Sep 14, 2026

Castle Biosciences (CSTL) CCO plans more stock sales under 10b5-1 plan - Stock Titan

Sep 14, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com

Sep 14, 2026

Sep 11, 2026

Preset sale plan at Castle Biosciences (CSTL) covers 29K shares - Stock Titan

Sep 11, 2026

Sep 10, 2026

Castle Biosciences, Inc.JAAD Publication Shows Improved Performance of DecisionDx-SCC - marketscreener.com

Sep 10, 2026

Responsive Playbooks and the CSTL Inflection - Stock Traders Daily

Sep 10, 2026